Advertisement

Pharmacologic Vitreolysis: Clinical Trial Data

Chapter
  • 1.1k Downloads
Part of the Essentials in Ophthalmology book series (ESSENTIALS)

Abstract

Pharmacologic vitreolysis refers to the administration of an agent to induce vitreous liquefaction and/or vitreoretinal separation in an attempt to treat vitreoretinal disorders. Enzymes that target one or more of the substrates that make up the vitreous and/or the “molecular glue” at the vitreoretinal interface have received the most attention in the search for a safe and effective pharmacologic vitreolytic agent. Although there is currently no pharmacologic therapy approved for treatment of diseases of the vitreo-macular interface, encouraging clinical results have been reported in recent years. The results of available clinical evaluations of the following agents are discussed in this chapter: collagenase, hyaluronidase, vitreosolve, tissue plasminogen activator, plasmin, and ocriplasmin.

Keywords

Diabetic Retinopathy Tissue Plasminogen Activator Macular Hole Diabetic Macular Edema Proliferative Diabetic Retinopathy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

References

  1. Abrishami M, Moosavi MN, Shoeibi N, Hosseinpoor SS (2011) Intravitreal tissue plasminogen activator to treat refractory diabetic macular edema by induction of posterior vitreous detachment. Retina 31(10):2065–2070PubMedCrossRefGoogle Scholar
  2. Akiba J, Arzabe CW, Trempe CL (1990) Posterior vitreous detachment and neovascularization in diabetic retinopathy. Ophthalmology 97:889–891PubMedCrossRefGoogle Scholar
  3. Avunduk A, Cetinkaya K, Kapicioglu Z, Kaya C (1997) The effect of posterior vitreous detachment on the prognosis of branch retinal vein occlusion. Acta Ophthalmol Scand 75:441–442PubMedCrossRefGoogle Scholar
  4. Azzolini C, D’Angelo A, Maestranzi G et al (2004) Intrasurgical plasmin enzyme in diabetic macular edema. Am J Ophthalmol 138:560–566PubMedCrossRefGoogle Scholar
  5. Banker AS, Freeman WR, Kim JW, Munguia D, Azen SP (1997) Vision-threatening complications of surgery for full-thickness macular holes. Vitrectomy for Macular Hole Study Group. Ophthalmology 104:1442–1453PubMedCrossRefGoogle Scholar
  6. Benz MS, Packo KH, Gonzalez V, Pakola S, Bezner D, Haller JA, Schwartz SD (2010) A placebo-controlled trial of microplasmin intravitreous injection to facilitate posterior vitreous detachment before vitrectomy. Ophthalmology 117:791–797PubMedCrossRefGoogle Scholar
  7. Bishop PN (2000) Structural macromolecules and supramolecular organisation of the vitreous gel. Prog Retin Eye Res 19:323–344PubMedCrossRefGoogle Scholar
  8. Cheng L, Azen SP, El-Bradey MH et al (2001) Duration of vitrectomy and postoperative cataract in the vitrectomy for macular hole study. Am J Ophthalmol 132:881–887PubMedCrossRefGoogle Scholar
  9. de Smet MD, Gandorfer A, Stalmans P, Veckeneer M, Ferone E, Pakola S, Kampik A (2009a) Microplasmin intravitreal administration in patients with vitreomacular traction scheduled for vitrectomy: the MIVI I trial. Ophthalmology 116:1349–1355PubMedCrossRefGoogle Scholar
  10. de Smet MD, Valmaggia C, Zarranz-Ventura J, Willekens B (2009b) Microplasmin: ex vivo characterization of its activity in porcine vitreous. Invest Ophthalmol Vis Sci 50:814–819PubMedCrossRefGoogle Scholar
  11. Dugel PU, MIVI-TRUST Study Group (2011) A single injection of ocriplasmin for the treatment of symptomatic vitreomacular adhesion (sVMA): results of the Phase 3 MIVI-TRUST Program. Invest Ophthalmol Vis Sci 52(Suppl):6628Google Scholar
  12. Freeman WR, Azen SP, Kim JW, El-Haig W, Mishell DR, Bailey I (1997) Vitrectomy for the treatment of full-thickness stage 3 or 4 macular holes. Results of a multicentered randomized clinical trial. The Vitrectomy for Treatment of Macular Hole Study Group. Arch Ophthalmol 115:11–21PubMedCrossRefGoogle Scholar
  13. Gad Elkareem AM, Willekens B, Vanhove M, Noppen B, Stassen JM, de Smet MD (2010) Characterization of a stabilized form of microplasmin for the induction of posterior vitreous detachment. Curr Eye Res 35:909–915PubMedCrossRefGoogle Scholar
  14. Gandorfer A, Putz E, Welge-Lussen U, Gruterich M, Ulbig M, Kampik A (2001) Ultrastructure of the vitreoretinal interface following plasmin assisted vitrectomy. Br J Ophthalmol 85:6–10PubMedCrossRefGoogle Scholar
  15. Gandorfer A, Rohleder M, Sethi C et al (2004) Posterior vitreous detachment induced by microplasmin. Invest Ophthalmol Vis Sci 45:641–647PubMedCrossRefGoogle Scholar
  16. Gottlieb JL, Antoszyk AN, Hatchell DL, Saloupis P (1990) The safety of intravitreal hyaluronidase. A clinical and histologic study. Invest Ophthalmol Vis Sci 31:2345–2352PubMedGoogle Scholar
  17. Guillaubey A, Malvitte L, Lafontaine PO et al (2007) Incidence of retinal detachment after macular surgery: a retrospective study of 634 cases. Br J Ophthalmol 91:1327–1330PubMedCrossRefGoogle Scholar
  18. Haller JA (2011) The vitreomacular interface and ocriplasmin 2011. Presented at Retina 2011, Orlando, FL, USA, 21–22 October 2011, pp 1–2. http://www.aao.org/pdf/Retina-2011-Syllabus.pdf. Assessed 24 Feb 2012
  19. Haller JA, Qin H, Apte RS et al (2010) Vitrectomy outcomes in eyes with diabetic macular edema and vitreomacular traction. Ophthalmology 117:1087–1093PubMedCrossRefGoogle Scholar
  20. Hesse L, Chofflet J, Kroll P (1995) Tissue plasminogen activator as a biochemical adjuvant in vitrectomy for proliferative vitreoretinopathy. Ger J Ophthalmol 4:323–327PubMedGoogle Scholar
  21. Hikichi T, Yoshida A, Trempe CL (1995) Course of vitreomacular traction syndrome. Am J Ophthalmol 119:55–61PubMedGoogle Scholar
  22. Hikichi T, Yanagiya N, Kado M, Akiba J, Yoshida A (1999) Posterior vitreous detachment induced by injection of plasmin and sulfur hexafluoride in the rabbit vitreous. Retina 19:55–58PubMedCrossRefGoogle Scholar
  23. Hikichi T, Kado M, Yoshida A (2000) Intravitreal injection of hyaluronidase cannot induce posterior vitreous detachment in the rabbit. Retina 20:195–198PubMedCrossRefGoogle Scholar
  24. Hirata A, Takano A, Inomata Y, Yonemura N, Sagara N, Tanihara H (2007) Plasmin-assisted vitrectomy for management of proliferative membrane in proliferative diabetic retinopathy: a pilot study. Retina 27:1074–1078PubMedCrossRefGoogle Scholar
  25. Johnson MW (2010) Posterior vitreous detachment: evolution and complications of its early stages. Am J Ophthalmol 149:371–382PubMedCrossRefGoogle Scholar
  26. Kamei M, Estafanous M, Lewis H (2000) Tissue plasminogen activator in the treatment of vitreoretinal diseases. Semin Ophthalmol 15:44–50PubMedCrossRefGoogle Scholar
  27. Krebs I, Brannath W, Glittenberg C et al (2007) Posterior vitreomacular adhesion: a potential risk factor for exudative age-related macular degeneration? Am J Ophthalmol 144:741–746PubMedCrossRefGoogle Scholar
  28. Kuppermann BD, Quiroz Mercado H, Graue-Wiechers F, Thomas EL, Calvillo PN, Grillone LR (2002) Effect of intravitreous hyaluronidase (Vitrase®) on progression of diabetic retinopathy in humans. Invest Ophthalmol Vis Sci, ARVO, May 5, 2002Google Scholar
  29. Kuppermann BD, Thomas EL, de Smet MD, Grillone LR for the vitrase for vitreous hemorrhage study groups (2005a) Pooled efficacy results from two multinational randomized controlled clinical trials of a single intravitreous injection of highly purified ovine hyaluronidase (Vitrase) for the management of vitreous hemorrhage. Am J Ophthalmol 140:573–584Google Scholar
  30. Kuppermann BD, Thomas EL, de Smet MD, Grillone LR for the vitrase for vitreous hemorrhage study groups (2005b) Safety results of two Phase 3 trials of an intravitreous injection of highly purified ovine hyaluronidase (Vitrase) for the management of vitreous hemorrhage. Am J Ophthalmol 140:585–597Google Scholar
  31. Le Goff MM, Bishop PN (2008) Adult vitreous structure and postnatal changes. Eye (Lond) 22:1214–1222CrossRefGoogle Scholar
  32. Le Mer Y, Korobelnik JF, Morel C, Ullern M, Berrod JP (1999) TPA-assisted vitrectomy for proliferative diabetic retinopathy: results of a double-masked, multicenter trial. Retina 19:378–382PubMedCrossRefGoogle Scholar
  33. Li X, Shi X, Fan J (2002) Posterior vitreous detachment with plasmin in the isolated human eye. Graefes Arch Clin Exp Ophthalmol 240:56–62PubMedCrossRefGoogle Scholar
  34. Liotta LA, Goldfarb RH, Brundage R, Siegal GP, Terranova V, Garbisa S (1981) Effect of plasminogen activator (urokinase), plasmin, and thrombin on glycoprotein and collagenous components of basement membrane. Cancer Res 41:4629–4636PubMedGoogle Scholar
  35. Margherio AR, Margherio RR, Hartzer M, Trese MT, Williams GA, Ferrone PJ (1998) Plasmin enzyme-assisted vitrectomy in traumatic pediatric macular holes. Ophthalmology 105:1617–1620PubMedCrossRefGoogle Scholar
  36. Melberg NS, Williams DF, Balles MW et al (1995) Vitrectomy for vitreomacular traction syndrome with macular detachment. Retina 15:192–197PubMedCrossRefGoogle Scholar
  37. Mojana F, Cheng L, Bartsch DU et al (2008) The role of abnormal vitreomacular adhesion in age-related macular degeneration: spectral optical coherence tomography and surgical results. Am J Ophthalmol 146:218–227PubMedCrossRefGoogle Scholar
  38. Moorhead LC, Radtke N (1985) Enzyme-assisted vitrectomy with bacterial collagenase. Pilot human studies. Retina 5:98–100PubMedCrossRefGoogle Scholar
  39. Murakami T, Takagi H, Obashi H et al (2007) Role of posterior vitreous detachment induced by intravitreal tissue plasminogen activator in macular edema with central retinal artery occlusion. Retina 27(8):1031–1037PubMedCrossRefGoogle Scholar
  40. Narayanan R, Kuppermann BD (2009) Hyaluronidase for pharmacologic vitreolysis. Dev Ophthalmol 44:20–25PubMedGoogle Scholar
  41. Nasrallah F, Jalkh A, Van Coppenolle F (1988) The role of the vitreous in diabetic macular edema. Ophthalmology 95:1335–1339PubMedCrossRefGoogle Scholar
  42. O’Neill R, Shea M (1973) The effects of bacterial collagenase in rabbit vitreous. Can J Ophthalmol 8:366–370PubMedGoogle Scholar
  43. Ramkissoon YD, Aslam SA, Shah SP, Wong SC, Sullivan PM (2010) Risk of iatrogenic peripheral retinal breaks in 20-G pars plana vitrectomy. Ophthalmology 117:1825–1830PubMedCrossRefGoogle Scholar
  44. Recchia FM, Scott IU, Brown GC, Brown MM, Ho AC, Ip MS (2010) Small-gauge pars plana vitrectomy: a report by the American Academy of Ophthalmology. Ophthalmology 117:1851–1857PubMedCrossRefGoogle Scholar
  45. Rizzo S, Belting C, Genovesi-Ebert F, Di Bartolo E (2010) Incidence of retinal detachment after small-incision, sutureless pars plana vitrectomy compared with conventional 20-gauge vitrectomy in macular hole and epiretinal membrane surgery. Retina 30:1065–1071PubMedCrossRefGoogle Scholar
  46. Robison CD, Krebs I, Binder S et al (2009) Vitreomacular adhesion in active and end-stage age- related macular degeneration. Am J Ophthalmol 148:79–82PubMedCrossRefGoogle Scholar
  47. Sakuma T, Tanaka M, Inoue M, Mizota A, Souri M, Ichinose A (2005a) Efficacy of autologous plasmin for idiopathic macular hole surgery. Eur J Ophthalmol 15:787–794PubMedGoogle Scholar
  48. Sakuma T, Tanaka M, Mizota A, Inoue J, Pakola S (2005b) Safety of in vivo pharmacologic vitreolysis with recombinant microplasmin in rabbit eyes. Invest Ophthalmol Vis Sci 46:3295–3299PubMedCrossRefGoogle Scholar
  49. Sakuma T, Tanaka M, Inoue J, Mizota A, Souri M, Ichinose A (2006) Use of autologous plasmin during vitrectomy for diabetic maculopathy. Eur J Ophthalmol 16:138–140PubMedGoogle Scholar
  50. Sakuma T, Mizota A, Inoue J, Tanaka M (2010) Intravitreal injection of autologous plasmin enzyme for macular edema associated with branch retinal vein occlusion. Am J Ophthalmol 150(6):876–882PubMedCrossRefGoogle Scholar
  51. Sebag J (1998) Pharmacologic vitreolysis. Retina 18:1–3PubMedCrossRefGoogle Scholar
  52. Sebag J (2004) Anomalous posterior vitreous detachment: a unifying concept in vitreo-retinal disease. Graefes Arch Clin Exp Ophthalmol 242:690–698PubMedCrossRefGoogle Scholar
  53. Sebag J (2005) Molecular biology of pharmacologic vitreolysis. Trans Am Ophthalmol Soc 103:473–494PubMedGoogle Scholar
  54. Sebag J (2009) Pharmacologic vitreolysis – premise and promise of the first decade. Retina 29:871–874PubMedCrossRefGoogle Scholar
  55. Sonmez K, Capone A Jr, Trese MT, Williams GA (2008) Vitreomacular traction syndrome: impact of anatomical configuration on anatomical and visual outcomes. Retina 28:1207–1214PubMedCrossRefGoogle Scholar
  56. Stalmans P, Delaey C, de Smet MD, van Dijkman E, Pakola S (2010) Intravitreal injection of microplasmin for treatment of vitreomacular adhesion: results of a prospective, randomized, sham-controlled phase II trial (the MIVI-IIT trial). Retina 30:1122–1127PubMedCrossRefGoogle Scholar
  57. Takahashi K, Nakagawa M, Ninomiya H et al (1993) Enzyme-assisted vitrectomy with collagenase. Jpn J Clin Ophthalmol 47:802–803Google Scholar
  58. Trese MT, Williams GA, Hartzer MK (2000) A new approach to stage 3 macular holes. Ophthalmology 107:1607–1611PubMedCrossRefGoogle Scholar
  59. Tsukahara Y, Honda S, Imai H et al (2007) Autologous plasmin-assisted vitrectomy for stage 5 retinopathy of prematurity: a preliminary trial. Am J Ophthalmol 144:139–141PubMedCrossRefGoogle Scholar
  60. Udaondo P, Diaz-Llopis M, Garcia-Delpech S, Salom D, Romero FJ (2011) Intravitreal plasmin without vitrectomy for macular edema secondary to branch retinal vein occlusion. Arch Ophthalmol 129:283–287PubMedCrossRefGoogle Scholar
  61. Uemura A, Nakamura M, Kachi S et al (2005) Effect of plasmin on laminin and fibronectin during plasmin-assisted vitrectomy. Arch Ophthalmol 123:209–213PubMedCrossRefGoogle Scholar
  62. Verstraeten TC, Chapman C, Hartzer M, Winkler BS, Trese MT, Williams GA (1993) Pharmacologic induction of posterior vitreous detachment in the rabbit. Arch Ophthalmol 111:849–854PubMedCrossRefGoogle Scholar
  63. Wang ZL, Zhang X, Xu X, Sun XD, Wang F (2005) PVD following plasmin but not hyaluronidase: implications for combination pharmacologic vitreolysis therapy. Retina 25:38–43PubMedCrossRefGoogle Scholar
  64. Wu WC, Drenser KA, Trese MT, Williams GA, Capone A (2007) Pediatric traumatic macular hole: results of autologous plasmin enzyme-assisted vitrectomy. Am J Ophthalmol 144:668–672PubMedCrossRefGoogle Scholar
  65. Wu W-C, Drenser KA, Lai M, Capone A, Trese MT (2008) Plasmin enzyme-assisted vitrectomy for primary and reoperated eyes with stage 5 retinopathy of prematurity. Retina 28(Suppl 3):S75–S80PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  1. 1.Clinical Development, Amakem NVIrvingtonUSA
  2. 2.Wills Eye InstitutePhiladelphiaUSA

Personalised recommendations